Biological therapy for the treatment of prepouch ileitis: a retrospective observational study from three centers
Received 7 July 2018
Accepted for publication 12 November 2018
Published 11 December 2018 Volume 2018:11 Pages 461—465
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Amy Norman
Peer reviewer comments 3
Editor who approved publication: Dr Anastasios Koulaouzidis
Jonathan P Segal,1,2 Matteo Rottoli,3 Richard K Felwick,4 Guy HT Worley,1,2 Simon D McLaughlin,4 Carlo Vallicelli,3 Paul Bassett,5 Omar D Faiz,1,2 Ailsa L Hart,1,2 Susan K Clark1,2
1Inflammatory Bowel Disease Department, St Mark’s Hospital, Harrow, UK; 2Department of Surgery and Cancer, Imperial College, London, UK; 3Surgery of the Alimentary Tract, Sant’Orsola – Malpighi Hospital, Alma Mater Studiorum University of Bologna, Bologna, Italy; 4Department of Gastroenterology, The Royal Bournemouth and Christchurch Hospitals, Bournemouth, UK; 5Statsconsultancy Ltd, Amersham, UK
Aim: Prepouch ileitis (PPI) is inflammation of the ileum proximal to an ileoanal pouch, usually associated with pouchitis. The treatment of PPI as a specific entity has been poorly studied, but it is generally treated concurrently with pouchitis. This to our knowledge is the largest study to explore the efficacy of biologics for the specific treatment of PPI.
Methods: This was a retrospective observational study reporting outcomes following biological treatment in patients with PPI across three centers. Data were collected between January 2004 and February 2018 from two centers in the UK and one center in Italy. Outcomes included the continued presence of PPI following biologic therapy, pouch failure defined by the need for an ileostomy, and remission of PPI defined by the absence of any prepouch inflammation on endoscopic assessment within a year of biologic therapy.
Results: There were 29 patients in our cohort. On last endoscopic follow-up, 20/29 still had endoscopic evidence of PPI, seven had achieved endoscopic remission and avoided an ileostomy, and two had no endoscopic follow-up. In our cohort 11 patients had an ileostomy after a median time from starting a biologic of 25 months (range 14–91).
Conclusion: Biologics fail to induce endoscopic remission of PPI in the majority of patients. Just under one-third patients with PPI coexistent with pouchitis can achieve endoscopic remission with biologics. In a large proportion of patients with PPI, surgery may be required despite biologic use.
Keywords: pouch, biologics, prepouch ileitis, pouchitis, restorative proctocolectomy, infliximab
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]